Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Volume: 25, Issue: 5, Pages: e808 - e815
Published: Nov 19, 2019
Abstract
Background Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) immune checkpoint blockade with chemotherapy could overcome these barriers. Here we present results of a phase Ib trial combining ipilimumab and gemcitabine in advanced PDAC. Materials...
Paper Details
Title
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Published Date
Nov 19, 2019
Volume
25
Issue
5
Pages
e808 - e815
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History